Funding agencies: This work was supported by Abbott Healthcare B.V. (formerly Solvay Pharmaceuticals Laboratories).
Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats
Article first published online: 2 NOV 2012
Copyright © 2012 Movement Disorders Society
Volume 28, Issue 8, pages 1072–1079, July 2013
How to Cite
Papathanou, M., van der Laan, R., Jenner, P., Rose, S. and McCreary, A. C. (2013), Levodopa infusion does not decrease the onset of abnormal involuntary movements in parkinsonian rats. Mov. Disord., 28: 1072–1079. doi: 10.1002/mds.25218
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the Acknowledgments section online.
- Issue published online: 12 AUG 2013
- Article first published online: 2 NOV 2012
- Manuscript Accepted: 30 AUG 2012
- Manuscript Revised: 22 AUG 2012
- Manuscript Received: 17 APR 2012
This article has been cited by:
- 1The Novel 5-HT1A Receptor Agonist, NLX-112 Reduces L-DOPA-induced Abnormal Involuntary Movements in Rat: a Chronic Administration Study with Microdialysis Measurements, Neuropharmacology, 2016,, , ,
- 2NLX-112, a novel 5-HT1A receptor agonist for the treatment of l-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat, Experimental Neurology, 2015, 271, 335, , , , , , , , ,